The American Cancer Society Journals estimates that there will be 1.9 million additional cancer diagnoses and 609,820 million cancer deaths this year.
The deadly disease affects tens of millions of people globally and causes millions of deaths across the world every year. Consequently, researchers are always looking for safer and more effective ways of preventing, detecting, and treating all kinds of cancers.
Researchers from India’s Tata Memorial Center have found evidence showing that nutraceuticals, which are food extracts that have health benefits on top of their nutritional value, may have promise in the prevention and treatment of cancer.
The team demonstrated that a pre-oxidant mixture of resveratrol and copper (R-Cu) had therapeutic benefits in patients who were undergoing chemotherapy to treat advanced gastric cancer. Resveratrol is a type of plant micronutrient called polyphenols that allow plants to survive disease attacks or drought.
Polyphenols occur in plant foods like peanuts, grapes, and berries and they have anti-inflammatory properties as well as antioxidant properties that can protect you against conditions like diabetes, Alzheimer’s disease, and cancer.
Cells release chromatin particles that are cell-free (cfChPs) into the circulatory system. Research over the past two decades has revealed that once they enter the bloodstream, cfChPs can enter healthy cells, integrate into their genomes, and cause the development of several diseases by inducing apoptotic responses and dsDNA breaks.
Dr. Indraneel Mittra, who’s the Chair of Translational Research at the medical institution, notes that the chemo-toxicity associated with chemotherapy isn’t completely caused by chemotherapy drugs.
He says that as the first cells start to die at the onset of chemotherapy treatment, they release cfChPs that enter host cells and begin a cycle of DNA damage and inflammation that inevitably prolong the toxicity of the treatment.
The recent Tata Memorial Center study found that an apro-oxidant mixture of resveratrol and copper (R-Cu) encouraged the generation of free oxygen radicals which have the ability to inactivate cfChPs. This theoretically reduces the cascading effect of DNA damage and inflammation caused by the cfChPs and minimizes the length and intensity of chemotherapy toxicity.
The research team has now launched a phase II clinical trial to investigate the synergetic effects of administering R-Cu to patients receiving chemotherapy treatment for advanced gastric cancer.
The aim was to determine if R-Cu could reduce the grade ≥ 3 toxicity associated with docetaxel-based chemotherapies by inactivating cfChPs.
Researchers found that the nutraceutical reduced the incidence of non-hematological toxicities as well as docetaxel exposure without reducing the efficacy and survivability of the treatment.
Dr. Mittra, one of the corresponding authors for the study, concluded that their evidence showed that nutraceuticals like R-Cu had the potential to be a new non-toxic and cost-effective agent in the treatment of cancer, metastasis prevention, and combating other diseases.
The fight against cancer is being waged on different fronts, and when those efforts of actors like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) and other teams yield the expected results, patients stand a higher chance to survive their diagnoses and enjoy better quality lives.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
